Advanced Solutions
for Advanced Pathology
GATA3 (L50-823)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45652 IMPATH GATA3 RTU M (L50-823)
50 Tests
45639 GATA3 RTU M (L50-823)
7 ml Ready To Use
45622 GATA3 0,1 M (L50-823)
100 µl liquid Concentrated
45623 GATA3 1 M (L50-823)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Breast carcinoma, Urothelial
carcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
/k
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
GATA3 (GATA binding protein 3 to DNA sequence [A/T]GATA[A/G]) is a zinc finger transcription factor and plays an important role in promoting
and directing cell proliferation, development, and differentiation in many tissues and cell types. GATA3 expression is primarily seen in breast
carcinoma and urothelial carcinoma and only rarely found in tumors from other organs, such as endometrial endometrioid adenocarcinoma.
GATA3 is expressed in all breast lobular carcinomas and 91% of invasive ductal carcinomas (grade I, 100%; grade II, 89% and grade III, 86%).
GATA3 expression seems to be lower in luminal B subtype breast carcinoma. It has also been reported that GATA3 expression is correlated with
the status of ER, PR and Her2 in breast carcinoma. GATA3 expression is found in urothelial carcinoma, especially in invasive and high grade
tumors. Therefore, anti-GATA3 can be used in a panel of antibodies for diagnosis of unknown primary carcinoma, when carcinomas of the breast
or bladder are a possibility.
Carcinomas
GATA3 S100P PAX-8 TTF-1 Napsin A HBME-1 CDX-2 Arginase-1 CA IX Cadherin-17
Breast Carcinoma
+
-
-
-
-
-
-
-
+
-
Lung Adenocarcinoma
-
-
-
+
+
-
-
-
-
-
Thyroid Carcinoma
-
-
+
+
-
+
-
-
-
Gastric Adenocarcinoma
-
-
-
-
-
-
+
-
-/+
Colon Adenocarcinoma
-
-
-
-
-
-
+
-
+
Pancreatic Ductal
Carcinoma
-
+
-
-
-
-
+
-
-/+
Hepatocellular Carcinoma
-
-
-
-
-
-
-
+
-
Urothelial Carcinoma
+
+
-
-
-
-
-
-
-
Renal Cell Carcinoma
-
-
+
-
-/+
-
-
-
+
-
Reference
1. Higgins JP, et al. Am J Surg Pathol. 2007; 31:673–680.
2. Liu H, et al. Am J Clin Pathol. 2012; 138:57-64.
3. Miettinen M, et al. Am J Surg Pathol. 2014; 38:13-22.
123
